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Chronic Kidney Disease as a Potent Risk Modiﬁer for
CAD in Diabetics*
Jeffrey C. Fink, MD
Baltimore, MarylandWith the demographic shift in the U.S. to an older
and heavier population, there has been a well-
documented increase in the incidence of diabetes
mellitus (1). Paralleling this rise in diabetes has
been a growth in the number of Americans with
chronic kidney disease (CKD). Estimates of the
number of adults with CKD and reduced kidney
See page 734
function are reported to be over 16 million (2). In
fact, there is a substantial overlap of the 2 diseases,
with a majority of patients with CKD also having
diabetes, and both diabetes and CKD are strong
risk factors for coronary heart disease (CHD) (3).
Although end-stage renal disease is often expected
as the disease outcome of CKD, a majority of
patients with CKD are likely to die of CHD before
reaching end-stage renal disease (4–6).
The timely and accurate diagnosis of CHD is a
challenge in those patients who have a preponder-
ance of traditional cardiac risk factors along with
diabetes and CKD. Such individuals might present
with silent ischemia or atypical coronary syndromes
or are not ideal candidates for invasive diagnostic
testing (7). It is in this population that effective
noninvasive strategies are needed to assist in CHD
risk-stratification and guide cardiac medical man-
agement. However, when assessing patients for
their likelihood of CHD and their prognosis when
CHD is present, it is important to determine how
much high-risk comorbidities such as diabetes and
CKD affect the initial assessment of risk for CHD
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the Department of Medicine, Division of Nephrology, at the
University of Maryland School of Medicine, Baltimore, Maryland.and then to consider how the use of a diagnostic test
modifies that baseline risk and improves the pre-
dictive power for that disease.
In this issue of iJACC, Hakeem et al. (8) retro-
spectively examined the impact of CKD and diabe-
tes in relation to myocardial perfusion defects and
both cardiac and all-cause mortality over a mean of
2 years. The patient cohort consisted of 1,747
patients with “known or suspected” CHD who
underwent noninvasive cardiac testing with myo-
cardial perfusion single-photon emission computed
tomography (MPS) for evaluation of ischemia.
CKD (defined as an estimated glomerular filtration
rate [eGFR] of 60 ml/min/1.73 m2) was present
in 20% of the subjects, with approximately the same
proportion having diabetes alone and 16% suffering
from both CKD and diabetes. The authors showed
that presence of CKD alone, with and without
diabetes, conferred a several-fold higher risk of
cardiac death for the various strata of MPS perfu-
sion defects. The incidence of death was higher
with increasing severity of stress perfusion defects in
all disease sub-categories, but with the relationship
most pronounced in the group with both CKD and
diabetes. A normal MPS conferred a lower risk in
CKD patients with and without diabetes. In mul-
tivariate analysis, the presence of both CKD and
diabetes were highly predictive of cardiovascular
death. Likewise, perfusion defects on stress imaging
and depressed ejection fraction were also significant
predictors of cardiovascular death. The investigators
concluded that both eGFR and myocardial perfu-
sion defects were important factors in risk-
stratification of patients being evaluated for CHD,
especially in patients with diabetes mellitus.
Patients with CKD have a confluence of both
traditional and nontraditional risk factors for car-
diovascular disease. Beyond exhibiting a cluster of
traditional Framingham risk factors (9), patients
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747ith CKD are subject to anemia, volume overload,
eft ventricular hypertrophy, poor vascular compli-
nce, and excess oxidative stress coronary calcifica-
ion, among others that have yet to be fully char-
cterized (10). Clearly, patients with CKD have a
omplex metabolic milieu, and to what extent diabetes
ompounds this environment thereby raising the risk
f CHD is unknown. In nondiabetic pre-dialysis
KD patients, we recently demonstrated a significant
nverse correlation between myocardial glucose use in
mol/min/100 g and eGFR employing quantitative
18-fluorodeoxyglucse positron emission tomography
s a means to measure myocardial metabolic changes
11). Myocyte-to-capillary mismatch, which is a
rogressive disorder in CKD, accrues with loss of
enal function and is associated with a diminished
ascular supply relative to the number and volume
f functioning myocytes. The oxygen-poor setting
ight lead to diffuse myocardial ischemia with a
hift in cardiac energetics from a predominance of
erobic to anaerobic metabolism, where glucose is
he primary fuel. This pathologic transformation
hat eventually promotes myocardial fibrosis is most
vident in end-stage renal disease and is associated
ith excessive mortality (12–15). Thus, myocardial
schemia and its metabolic consequences in CKD
ight account for a significant portion of the
xcessive cardiovascular morbidity and mortality
bserved across all stages of kidney disease.
Given the strength of CKD as a predictor of CHD
nd adverse patient outcomes in the setting of diabe-
es, one needs to ask what the findings of Hakeem et
l. (8) inform us about cardiac risk stratification of this
igh-risk disease population. Although the cohort
ssembled for the study was substantial, it included
atients who underwent MPS with “known or sus-Soc Nephrol 2004;15:1307–15. 489–95.he same relationship between reduced renal function
nd MPS might not necessarily apply to a comparable
opulation not suspected to have CHD. Perhaps
ore importantly, in clarifying the roles of CKD
iagnosis and the use of MPS in stratifying cardiovas-
ular risk in diabetic patients, is the determination of
ow each piece of clinical information alters prior
robability estimates of the disease of interest (16). It
ould be useful in follow-up analysis to determine the
ncremental utility of MPS results above and beyond
etermination of diabetic status and eGFR in predict-
ng cardiac death. Whether MPS provides additive
isk stratification to hemoglobin A1C, proteinuria,
nd other biomarkers would be an important study to
ndertake next.
Finally, accepting the notion that CKD represents
potent modifier to the risk of CHD in diabetes, one
ust ask how the acquired information from cardio-
ascular risk stratification impacts disease manage-
ent and alters outcomes in these patients. Unfortu-
ately, patients with CKD who have CHD do
elatively poorly with established cardiac interventions,
nd these adverse outcomes are enhanced in diabetic
atients with CKD. Coronary artery revascularization
eads to significantly inferior outcomes in patients
ith CKD relative to their counterparts with CHD
nd no CKD (17,18). Thus, the diagnostic approach
ndorsed by MPS must be supplemented by a “new”
et of therapeutic interventions that can improve the
ardiovascular outcome of patients with CKD, espe-
ially in the presence of diabetes mellitus.
eprint requests and correspondence: Dr. Jeffrey C. Fink,
niversity of Maryland Medical Center, Department of
edicine, Division of Nephrology, 22 South Greene Street,
oom N3W143, Baltimore, Maryland 21201. E-mail:
ected” CHD and were likely examined for cause. jfink@medicine.umaryland.edu.E F E R E N C E S
1. Kirtland KA, Li YF, Geiss LS,
Thompson TJ. State-specific inci-
dence of diabetes among adults—
participating states, 1995–1997 and
2005–2007. MMWR Morb Mortal
Wkly Rep 2008;57:1169–73.
2. Coresh J, Selvin E, Stevens LA, et al.
Prevalence of chronic kidney disease
in the United States. JAMA 2007;
298:2038–47.
3. Weiner DE, Tighiouart H, Amin
MG, et al. Chronic kidney disease as a
risk factor for cardiovascular disease
and all cause mortality–a pooled anal-
ysis of community based studies. J Am4. Go AS, Chertow GM, Fan D,
McCulloch CE, Hsu CY. Chronic
kidney disease and the risks of death,
cardiovascular events, and hospitaliza-
tion. N Engl J Med 2004;351:1296–
305.
5. Collins AJ, Li S, Gilbertson DT, Liu
J, Chen SC, Herzog CA. Chronic
kidney disease and cardiovascular dis-
ease in the Medicare population. Kid-
ney Int 2003;87:S24–31.
6. Foley RN, Murray AM, Li S, et al.
Chronic kidney disease and the risk
for cardiovascular disease, renal re-
placement, and death in the United
States Medicare population, 1998 to
1999. J Am Soc Nephrol 2005;16:7. Sosnov J, Lessard D, Goldberg RJ,
Yarzebski J, Gore JM. Differential
symptoms of acute myocardial infarc-
tion in patients with kidney disease: a
community-wide perspective. Am J
Kidney Dis 2006;47:378–84.
8. Hakeem A, Bhatti S, Karmali KN,
et al. Impact of renal function on risk
stratification of diabetic and nondia-
betic patients undergoing evaluation
for coronary artery disease. J Am Coll
Cardiol Img 2010;3:734–45.
9. Culleton BF, Larson MG, Wilson
PW, Evans JC, Parfrey PS, Levy D.
Cardiovascular disease and mortality
in a community-based cohort with
mild renal insufficiency. Kidney Int
1999;56:2214–9.
11
1
1
1
K
k
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 7 , 2 0 1 0
J U L Y 2 0 1 0 : 7 4 6 – 8
Fink
Editorial Comment
7480. Zoccali C. Traditional and emerging
cardiovascular and renal risk factors:
an epidemiologic perspective. Kidney
Int 2006;70:26–33.
1. Fink JC, Lodge MA, Smith MF, et al.
Pre-clinical myocardial metabolic al-
terations in chronic kidney disease.
Cardiology 2010. In press.
2. Nishimura M, Tsukamoto K, Hasebe
N, Tamaki N, Kikuchi K, Ono T.
Prediction of cardiac death in hemo-
dialysis patients by myocardial fatty
acid imaging. J Am Coll Cardiol
2008;51:139–45.
3. Dilsizian V, Fink J. Deleterious effect
of altered myocardial fatty acid metab-
olism in kidney disease. J Am Coll
Cardiol 2008;51:146–8.14. Mark PB, Johnston N, Goenning BA,
et al. Redefinition of uremic cardio-
myopathy by contrast enhanced car-
diac magnetic resonance imaging.
Kidney Int 2006;69:1839–45.
15. Pizzarelli F, Dattolo P, Ferdeghini
EM, Morales MA. Parameters de-
rived by ultrasonic myocardial charac-
terization in dialysis patients are as-
sociated with mortality. Kidney Int
2005;68:1320–5.
16. Cornell J, Mulrow CD, Localio AR.
Diagnostic test accuracy and clinical
decision making. Ann Intern Med
2008;149:904–6.
17. Cooper WA, O’Brien SM, Thourani
VH, et al. Impact of renal dysfunction
on outcomes of coronary artery bypass dsurgery: results from the Society of
Thoracic Surgeons National Adult
Cardiac Database. Circulation 2006;
113:1063–70.
8. Osten MD, Ivanov J, Eichhofer J,
et al. Impact of renal insufficiency
on angiographic, procedural, and in-
hospital outcomes following percuta-
neous coronary interventions. Am J
Cardiol 2008;101:780–5.
ey Words: diabetes y chronic
idney disease y coronary artery
isease y diagnosis.
